Antidementia medication can provide symptomatic improvements in patients with Alzheimer’s disease, but there is a lack of consensus guidance on when to start and stop treatment in the nursing home setting.
Methods
We describe utilization patterns of cholinesterase inhibitors (ChEI) and memantine for 3,50,197 newly admitted NH residents with dementia between 2011 and 2018.
Results
Overall, pre-admission use of antidementia medications declined from 2011 to 2018 (ChEIs: 44.5% to 36.9%; memantine: 27.4% to 23.2%). Older age, use of a feeding tube, and greater functional dependency were associated with lower odds of ChEI initiation. Coronary artery disease, parenteral nutrition, severe aggressive behaviors, severe cognitive impairment, and high functional dependency were associated with discontinuation of ChEIs. Comparison of clinical factors related to anti-dementia drug treatment changes from pre to post NH admission in 2011 and 2018 revealed a change toward lower likelihood of initiation of treatment among residents with more functional dependency and those with indicators of more complex illness as well as a change toward higher likelihood of discontinuation in residents having 2 or more hospital stays.
Conclusions
These prescribing trends highlight the need for additional research on the effects of initiating and discontinuing antidementia medications in the NH to provide clear guidance for clinicians when making treatment decisions for individual residents.
BirksJSHarveyRJ. Donepezil for dementia due to alzheimer’s disease. Cochrane Database Syst Rev. 2018;6(6):Cd001190. doi:10.1002/14651858.CD001190.pub3.
3.
LiDDZhangYHZhangWZhaoP. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of alzheimer’s disease. Front Neurosci. 2019;13:472. doi:10.3389/fnins.2019.00472.
4.
McShaneRWestbyMJRobertsE, et al.Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154. doi:10.1002/14651858.CD003154.pub6.
5.
SeitzDPGruneirAConnDKRochonPA. Cholinesterase inhibitor use in U.S. nursing homes: Results from the national nursing home survey. J Am Geriatr Soc. 2009;57(12):2269-2274. doi:10.1111/j.1532-5415.2009.02552.x.
6.
ParsonsCBriesacherBAGivensJLChenYTjiaJ. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253-1259. doi:10.1111/j.1532-5415.2011.03478.x.
7.
PedoneCLapaneKLMorVBernabeiR. Donepezil use in US nursing homes. Aging Clin Exp Res. 2004;16(1):60-67. doi:10.1007/BF03324534.
8.
DybiczSBKeohaneDJErwinWGMcRaeTShahSN. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother. 2006;4(2):154-160. doi:10.1016/j.amjopharm.2006.06.002.
9.
NiznikJDZhaoXHeM, et al.Risk for health events after deprescribing acetylcholinesterase inhibitors in nursing home residents with severe dementia. J Am Geriatr Soc. 2020;68(4):699-707. doi:10.1111/jgs.16241.
10.
NiznikJDZhaoXHeM, et al.Impact of deprescribing AChEIs on aggressive behaviors and antipsychotic prescribing. Alzheimers Dement. 2020;16(4):630-640. doi:10.1002/alz.12054.
11.
DaielloLAOttBRLapaneKLReinertSEMachanJTDoreDD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74-83. doi:10.1016/j.amjopharm.2009.04.002.
12.
ShegaJWEllnerLLauDTMaxwellTL. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: A survey of hospice medical directors. J Palliat Med. 2009;12(9):779-783. doi:10.1089/jpm.2009.0059.
13.
ParsonsCLimWYLoyC, et al.Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 2021;2:CD009081. doi:10.1002/14651858.CD009081.pub2.
14.
O’ReganJLanctôtKLMazereeuwGHerrmannN. Cholinesterase inhibitor discontinuation in patients with alzheimer’s disease: A meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424-e1431. doi:10.4088/JCP.14r09237.
15.
FillitHHofbauerRKSetyawanJ, et al.Memantine discontinuation and the health status of nursing home residents with alzheimer’s disease. J Am Med Dir Assoc. 2010;11(9):636-644. doi:10.1016/j.jamda.2009.12.086.
16.
HowardRMcShaneRLindesayJ, et al.Nursing home placement in the donepezil and memantine in moderate to severe alzheimer’s disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2015;14(12):1171-1181. doi:10.1016/s1474-4422(15)00258-6.
17.
DeardorffWJFeenEGrossbergGT. The use of cholinesterase inhibitors across all stages of alzheimer’s disease. Drugs Aging. 2015;32(7):537-547. doi:10.1007/s40266-015-0273-x.
18.
ReeveEFarrellBThompsonW, et al.Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174-179. doi:10.5694/mja2.50015.
19.
O’BrienJTHolmesCJonesM, et al.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British association for psychopharmacology. J Psychopharmacol. 2017;31(2):147-168. doi:10.1177/0269881116680924.
20.
FillitHMDoodyRSBinasoK, et al.Recommendations for best practices in the treatment of alzheimer’s disease in managed care. Am J Geriatr Pharmacother. 2006;4(S9-S24):S25-S28. doi:10.1016/j.amjopharm.2006.10.001
21.
HerrmannNGauthierSLysyPG. Clinical practice guidelines for severe alzheimer’s disease. Alzheimers Dement. 2007;3(4):385-397. doi:10.1016/j.jalz.2007.07.007.
22.
RennBNAsghar-AliAAThielkeS, et al.A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatr. 2018;26(2):134-147. doi:10.1016/j.jagp.2017.09.027.
23.
DisalvoDLuckettTBennettADavidsonPMAgarM. Multidisciplinary perspectives on medication-related decision-making for people with advanced dementia living in long-term care: A critical incident analysis. Eur J Clin Pharmacol. 2020;76(4):567-578. doi:10.1007/s00228-019-02820-z.
24.
HerrmannNIsmailZCollinsR, et al.CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimers Dement. 2022;8(1):Article e12099. doi:10.1002/trc2.12099.
MorrisJNFriesBEMorrisSA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546-M553. doi:10.1093/gerona/54.11.m546.
27.
ThomasKSDosaDWysockiAMorV. The minimum data set 3.0 cognitive function scale. Med Care. 2017;55(9):e68-e72. doi:10.1097/MLR.0000000000000334.
28.
PerlmanCMHirdesJP. The aggressive behavior scale: a new scale to measure aggression based on the minimum data set. J Am Geriatr Soc. 2008;56(12):2298-2303. doi:10.1111/j.1532-5415.2008.02048.x.
29.
DaielloLA. Current issues in dementia pharmacotherapy. Am J Manag Care. 2007;13(Suppl 8):S198-S202.
30.
DouKXTanMSTanCC, et al.Comparative safety and effectiveness of cholinesterase inhibitors and memantine for alzheimer’s disease: A network meta-analysis of 41 randomized controlled trials. Alzheimer’s Res Ther. 2018;10(1):126. doi:10.1186/s13195-018-0457-9.
31.
Blanco-SilventeLCastellsXSaezM, et al.Discontinuation, efficacy, and safety of cholinesterase inhibitors for alzheimer’s disease: A meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16,106 patients. Int J Neuropsychopharmacol. 2017;20(7):519-528. doi:10.1093/ijnp/pyx012.
32.
MoretaMPBurgos-AlonsoNTorrecillaMMarco-ContellesJBruzos-CidonC. Efficacy of acetylcholinesterase inhibitors on cognitive function in alzheimer’s disease. Review of reviews. Biomedicines. 2021;9(11):1689. doi:10.3390/biomedicines9111689.
33.
TariotPNCummingsJLKatzIR, et al.A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590-1599.
34.
WinbladBKilanderLErikssonS, et al.Donepezil in patients with severe alzheimer’s disease: Double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367(9516):1057-1065. doi:10.1016/S0140-6736(06)68350-5.
35.
TariotPN. Medical management of advanced dementia. J Am Geriatr Soc. 2003;51(5):S305-S313. doi:10.1046/j.1532-5415.5156.x.
36.
CummingsJLKoumarasBChenMMirskiD. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3(3):137-148. doi:10.1016/s1543-5946(05)80020-0.
37.
BlackSEDoodyRLiH, et al.Donepezil preserves cognition and global function in patients with severe alzheimer disease. Neurology. 2007;69(5):459-469. doi:10.1212/01.wnl.0000266627.96040.5a.
38.
ProfyriELeungPHuntleyJOrgetaV. Effectiveness of treatments for people living with severe dementia: A systematic review and meta-analysis of randomised controlled clinical trials. Ageing Res Rev. 2022;82:101758. doi:10.1016/j.arr.2022.101758.
39.
HommaAImaiYTagoH, et al.Donepezil treatment of patients with severe alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008;25(5):399-407. doi:10.1159/000122961.
40.
FarlowMRGrossbergGTSadowskyCHMengXSomogyiM. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745-752. doi:10.1111/cns.12158.
41.
O'BrienJTBurnsA. Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British association for psychopharmacology. J Psychopharmacol. 2011;25(8):997-1019. doi:10.1177/0269881110387547.
42.
IhlRBuneviciusRFrolichL, et al.World federation of societies of biological psychiatry guidelines for the pharmacological treatment of dementias in primary care. Int J Psychiatr Clin Pract. 2015;19(1):2-7. doi:10.3109/13651501.2014.961931.
43.
RabinsPVRovnerBWRummansTSchneiderLSTariotPN. Guideline watch (october 2014): Practice guideline for the treatment of patients with alzheimer’s disease and other dementias. Focus. 2017;15(1):110-128. doi:10.1176/appi.focus.15106.
44.
SadowskyCHGalvinJE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med. 2012;25(3):350-366. doi:10.3122/jabfm.2012.03.100183.
45.
DoodyRSStevensJCBeckC, et al.Practice parameter: Management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology. Neurology. 2001;56(9):1154-1166. doi:10.1212/wnl.56.9.1154.
46.
TariotPNFederoffHJ. Current treatment for alzheimer disease and future prospects. Alzheimer Dis Assoc Disord. 2003;17(Suppl 4):S105-S113. doi:10.1097/00002093-200307004-00005.
47.
VeronikiAAAshoorHMRiosP, et al.Comparative safety and efficacy of cognitive enhancers for alzheimer’s dementia: A systematic review with individual patient data network meta-analysis. BMJ Open. 2022;12(4):Article e053012. doi:10.1136/bmjopen-2021-053012.
48.
KnightRKhondokerMMagillNStewartRLandauS. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3-4):131-151. doi:10.1159/000486546.
49.
BuckleyJSSalpeterSR. A risk-benefit assessment of dementia medications: Systematic review of the evidence. Drugs Aging. 2015;32(6):453-467. doi:10.1007/s40266-015-0266-9.
50.
LockhartIAMitchellSAKellyS. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with alzheimer’s disease: Systematic review of the “real-world” evidence. Dement Geriatr Cogn Disord. 2009;28(5):389-403. doi:10.1159/000255578.
51.
HapcaSBurtonJKCvoroVReynishEDonnanPT. Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older?Alzheimers Dement (N Y). 2019;5:431-440. doi:10.1016/j.trci.2019.07.011.
52.
LazzeroniLCHalbauerJDAshfordJW, et al.Memantine is associated with longer survival than donepezil in a veterans affairs prescription database, 1997 to 2008. J Alzheimers Dis. 2013;36(4):791-798. doi:10.3233/JAD-130662.
53.
LinWHLinCHHouPHLanTH. The effect of antidementia drugs on mortality in patients with alzheimer’s disease. J Psychopharmacol. 2019;33(8):986-993. doi:10.1177/0269881119845795.
54.
LiebermanOJLeeSZabinskiJ. Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. Alzheimers Dement. 2023;19:1742-1751. doi:10.1002/alz.12807.
55.
ZuinMCherubiniAVolpatoSFerrucciLZulianiG. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci Rep. 2022;12(1):12214. doi:10.1038/s41598-022-16476-w.
56.
XuHGarcia-PtacekSJönssonLWimoANordströmPEriksdotterM. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology. 2021;96(17):e2220-e2230. doi:10.1212/wnl.0000000000011832.
57.
TruongCRectoCLafontCCanoui-PoitrineFBelminJBLafuente-LafuenteC. Effect of cholinesterase inhibitors on mortality in patients with dementia: A systematic review of randomized and nonrandomized trials. Neurology. 2022;99:e2313-e2325. doi:10.1212/WNL.0000000000201161.
58.
WinbladBPoritisN. Memantine in severe dementia: Results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatr. 1999;14(2):135-146. doi:10.1002/(sici)1099-1166(199902)14:2<135::aid-gps906>3.0.co;2-0.
59.
PeskindERPotkinSGPomaraN, et al.Memantine treatment in mild to moderate alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatr. 2006;14(8):704-715. doi:10.1097/01.JGP.0000224350.82719.83.
60.
ReisbergBDoodyRStofflerA, et al.Memantine in moderate-to-severe alzheimer’s disease. N Engl J Med. 2003;348(14):1333-1341. doi:10.1056/NEJMoa013128.
61.
MatsunagaSKishiTNomuraI, et al.The efficacy and safety of memantine for the treatment of alzheimer’s disease. Expet Opin Drug Saf. 2018;17(10):1053-1061. doi:10.1080/14740338.2018.1524870.
62.
GuoJWangZLiuRHuangYZhangNZhangR. Memantine, donepezil, or combination therapy-what is the best therapy for alzheimer’s disease? A network meta-analysis. Brain Behav. 2020;10(11):e01831. doi:10.1002/brb3.1831.
63.
AtriAShaughnessyLWLocascioJJGrowdonJH. Long-term course and effectiveness of combination therapy in alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-221. doi:10.1097/WAD.0b013e31816653bc.
64.
GauthierSMolinuevoJL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe alzheimer’s disease. Alzheimers Dement. 2013;9(3):326-331. doi:10.1016/j.jalz.2011.11.005.
65.
AtriAHendrixSBPejovićV, et al.Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe alzheimer’s dementia: A pooled area under the curve analysis. Alzheimer's Res Ther. 2015;7(1):28. doi:10.1186/s13195-015-0109-2.
66.
CummingsJLSchneiderLTariotPNKershawPRYuanW. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with alzheimer’s disease. Am J Psychiatr. 2004;161(3):532-538. doi:10.1176/appi.ajp.161.3.532.
67.
CummingsJLaiTJHemrungrojnS, et al.Role of donepezil in the management of neuropsychiatric symptoms in alzheimer’s disease and dementia with lewy bodies. CNS Neurosci Ther. 2016;22(3):159-166. doi:10.1111/cns.12484.
68.
BallardCKalesHCLyketsosC, et al.Psychosis in alzheimer’s disease. Curr Neurol Neurosci Rep. 2020;20(12):57. doi:10.1007/s11910-020-01074-y.
69.
ZhangTLiuNCaoHWeiWMaLLiH. Different doses of pharmacological treatments for mild to moderate alzheimer’s disease: A bayesian network meta-analysis. Front Pharmacol. 2020;11:778. doi:10.3389/fphar.2020.00778.
70.
Garcia-GollarteFBaleriola-JulvezJFerrero-LopezICruz-JentoftAJ. Inappropriate drug prescription at nursing home admission. J Am Med Dir Assoc. 2012;13(1):e9-e15. doi:10.1016/j.jamda.2011.02.009.
71.
NiznikJDZhaoXHeM, et al.Factors associated with deprescribing acetylcholinesterase inhibitors in older nursing home residents with severe dementia. J Am Geriatr Soc. 2019;67(9):1871-1879. doi:10.1111/jgs.15985.
72.
MaclaganLCBronskillSECampitelliMA, et al.Resident-level predictors of dementia pharmacotherapy at long-term care admission: The impact of different drug reimbursement policies in ontario and saskatchewan. Can J Psychiatr. 2020;65(11):790-801. doi:10.1177/0706743720909293.
73.
MaclaganLCBronskillSEGuanJ, et al.Predictors of cholinesterase discontinuation during the first year after nursing home admission. J Am Med Dir Assoc. 2018;19(11):959-966. doi:10.1016/j.jamda.2018.07.020.
74.
KollerDHuaTBynumJP. Treatment patterns with antidementia drugs in the United States: Medicare cohort study. J Am Geriatr Soc. 2016;64(8):1540-1548. doi:10.1111/jgs.14226.
75.
McCarthyEPChangCHTiltonNKabetoMULangaKMBynumJPW. Validation of claims algorithms to identify alzheimer’s disease and related dementias. J Gerontol A Biol Sci Med Sci. 2022;77(6):1261-1271. doi:10.1093/gerona/glab373.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
